LLY director Jamere Jackson reports new stock acquisition on Form 4

Q: What did Eli Lilly (LLY) report in this Form 4 filing?

This Form 4 reports that director Jamere Jackson acquired additional common stock of Eli Lilly & Co in a reported transaction on 11/17/2025 .

Q: How many Eli Lilly (LLY) shares did the director acquire and at what price?

The director acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share , recorded as an acquisition transaction.

Q: What is the director's total Eli Lilly (LLY) share ownership after this transaction?

After the reported transaction, the director beneficially owns 9,635.494 shares of Eli Lilly common stock, held in direct ownership.

Q: What is the relationship of the reporting person to Eli Lilly (LLY)?

The reporting person, Jamere Jackson , is identified as a Director of Eli Lilly & Co on the Form 4.

Q: Was this Eli Lilly (LLY) transaction filed by more than one reporting person?

No. The filing indicates that the Form 4 was filed by one reporting person , not by a group or multiple filers.

Q: What is the purpose of SEC Form 4 for Eli Lilly (LLY) insiders?

Form 4 is used by company insiders, such as directors, to report changes in their beneficial ownership of the issuer's securities, including acquisitions and dispositions.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Eli Lilly & Co (LLY) director Jamere Jackson reported acquiring common stock of the company. On 11/17/2025, the reporting person acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share, coded as an acquisition transaction. Following this transaction, the director beneficially owns 9,635.494 shares of Eli Lilly common stock held directly. The filing was made as a Form 4 by a single reporting person in the capacity of a company director.

Insider Trade Summary

Net Buyer: 215.327 shares

Net Buy 1 txn

Insider JACKSON JAMERE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	215.327	$1,021.70	$220K

Holdings After Transaction: Common Stock — 9,635.494 shares (Direct)

FAQ

What did Eli Lilly (LLY) report in this Form 4 filing?

This Form 4 reports that director Jamere Jackson acquired additional common stock of Eli Lilly & Co in a reported transaction on 11/17/2025.

How many Eli Lilly (LLY) shares did the director acquire and at what price?

The director acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share, recorded as an acquisition transaction.

What is the relationship of the reporting person to Eli Lilly (LLY)?

The reporting person, Jamere Jackson, is identified as a Director of Eli Lilly & Co on the Form 4.

Does this Form 4 include any derivative securities for Eli Lilly (LLY)?

No derivative securities are reported as acquired, disposed of, or beneficially owned in Table II of this Form 4; only common stock is listed in Table I.

Was this Eli Lilly (LLY) transaction filed by more than one reporting person?

No. The filing indicates that the Form 4 was filed by one reporting person, not by a group or multiple filers.

What is the purpose of SEC Form 4 for Eli Lilly (LLY) insiders?

Form 4 is used by company insiders, such as directors, to report changes in their beneficial ownership of the issuer's securities, including acquisitions and dispositions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/18/2025 - 04:19 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JACKSON JAMERE

(Last)

(First)

(Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS

46285

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/17/2025		A		215.327	A	$1,021.7	9,635.494	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

Remarks:

	/s/ Jonathan Groff for Jamere Jackson, pursuant to authorization on file	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR